The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2016Characterization, Optimization and Validation of a Preformed Fibril Pre-clinical Model of Parkinson's Disease
Study Rationale:
New pre-clinical models have been developed to study the hypothesis that damaging forms of alpha-synuclein (protein involved in Parkinson's) spread across brain regions from a single... -
Research Grant, 2016Design and Identification of a LRRK2 Kinase Structural Surrogate
Study Rationale:
Due to the importance of the LRRK2 protein in Parkinson's disease (PD), many academic and industrial laboratories have attempted to solve the three-dimensional structure of the kinase...
-
Target Advancement Program, 2016Targeting the Transcriptional Regulator of Autophagy LMX1B for Parkinson's Disease Therapeutic Development
Study Rationale:
LMX1B is a transcription factor that plays an essential role in the development of dopaminergic neurons. We have recently described a new role for LMX1B in dopaminergic neurons as a... -
Target Advancement Program, 2016Role of LRRK2 in GCase-mediated Alterations in Lysosome Function and Alpha-synuclein Metabolism
Study Rationale:
Mutations in the lysosomal (enzyme storage unit) enzyme GCase are associated with an increased risk of Parkinson's disease (PD) and cause alpha-synuclein (protein associated with... -
Improved Biomarkers and Clinical Outcome Measures, 2016Brainstem and Olfactory System Biomarkers of Early Parkinson's Disease
Study Rationale:
There is a great need to identify Parkinson's disease (PD) in its earliest stages when interventions may prevent or slow neural degeneration. Given that the earliest brain pathology... -
Target Advancement Program, 2016GADD34 Inhibition as a Neuroprotective Strategy in Parkinson's Disease
The lack of disease-modifying therapies is a crucial deficiency in the treatment of Parkinson disease (PD). Using cellular models of PD, we have identified the protein GADD34 as a novel potential...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.